Lupin Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Record quarter, but moderation ahead: Revenue crossed INR 8,000 crores and EBITDA INR 2,400 crores for the first time, yet management flagged that U.S. competitive intensity on Tolvaptan and Mirabegron will pull results lower from Q2.
• U.S. anchors the story at \$1.1–1.2 bn: The full-year U.S. guide absorbs known headwinds and leans on base business volumes, injectable launches, and Pegfilgrastim to hold the line, with a return to growth promised only from FY28.
• Ex-U.S. is the quiet growth engine: India grew 13.9% and is guided to 1.2–1.3x IPM, while Europe (+83%) and Emerging Markets (+52%) delivered breakout quarters that management expects to sustain.
• Margins improved but face cost creep: Gross margin rose 330 bps YoY to 74.6%, yet staff costs jumped 28% and geopolitical cost increases have not yet flowed through inventory; full-year EBITDA is guided to ~25%.
• What to watch next quarter: The size of the Tolvaptan/Mirabegron step-down in the U.S. run-rate, whether the guided \$250–280 mn quarterly band holds, and any margin compression from raw-material cost pass-through.

U.S. Business: The Tolvaptan-Mirabegron Reset

• Q1 strength, Q2 reset: U.S. sales hit USD 366 mn, up 30% YoY in constant currency, driven by higher base volumes and Tolvaptan with no new competition in the quarter. From Q2, Apotex and Teva enter Tolvaptan, with a potential fourth entrant in September, while Mirabegron faces a full quarter of the pressure already visible in Q1.
• Tolvaptan endgame: Management expects a four-player market, pricing to decline, and some share redistribution, but also sees the molecule growing because only 40% of the market has converted to generics. The REMS program and specialty-pharmacy distribution should stretch the tail, though share will have to be given up.
• Quarterly run-rate guide: Revenues are expected to settle at USD 250–280 mn per quarter over the next couple of quarters, down from the Q1 peak, as the competitive reset plays out.
• FY28 growth pivot: The U.S. is expected to return to a growth trajectory only from FY28, built on the FY27 base, with full-year contributions from Pegfilgrastim, Apixaban 505(b)(2), and a wave of nasal sprays and injectables.

Vinita Gupta: "We expect the U.S. business to be in the USD 1.1 billion to USD 1.2 billion range, aided by growth in base business, our injectable launches, and contribution from Pegfilgrastim offsetting the additional competition in products like Mirabegron and Tolvaptan during the year."

Ex-U.S. Markets: The Diversification Payoff

• India formulations: Grew 13.9% YoY, with the core prescription business up 15.1% (1.1x IPM). Chronic share rose to ~67% from ~65% in FY26, and the diabetes segment surged 31.8% on Huminsulin® leadership and the Semaglutide launch. Management is confident of sustaining 1.2–1.3x IPM growth.
• Europe breakout: Sales grew 83% YoY, lifting Other Developed Markets to 14% of total sales (from 11% in FY26). Germany's shift of Ranibizumab and Aflibercept out of AOK tenders into branded opportunities, plus France doubling down on biosimilar substitution, create structural tailwinds. Management sees 10–20% growth over the next couple of years with expanding margins.
• Emerging Markets surge: Sales grew 52% YoY, led by Brazil (+117% in local currency on Dapagliflozin commercialization and Empagliflozin launch), South Africa, and the Philippines. Empagliflozin launches in Brazil and South Africa, plus Semaglutide in South Africa later this year, extend the runway.
• Biosimilars scaling: Pegfilgrastim is ramping with pleasantly surprising pricing, and management targets a couple of hundred million dollars across key markets in three years, with Aflibercept and Etanercept (FY30) in the pipeline. European biosimilar pricing on Lupin's products has been fairly stable.

Vinita Gupta: "We are very optimistic, very hopeful that Europe is going to increasingly become a more important geography for Lupin for certain, just given our portfolio of respiratory products, biosimilars overall, as well as the ophthalmology biosimilars, as well as the specialty portfolio."

Pipeline: Complex Generics, 505(b)(2)s, and the Respiratory Bet

• Three-year launch ambition: Lupin plans 50+ U.S. launches, including 10 exclusive first-to-files, 5 biosimilars, and 2–3 505(b)(2)s, with a goal of doubling the share of complex products in the U.S. business.
• Apixaban 505(b)(2) as the next material swing: A September goal date, with commercial quantities expected from January 2027 and a summer launch window offering 10–12 months before generics enter. Management sees it as potentially reaching Mirabegron/Tolvaptan scale, with a targeted channel approach and small commercial investment. The product was filed from the recently cleared Somerset facility.
• Respiratory pipeline inflection: Breo® (Ellipta) achieved successful pivotal PK and will be filed this fiscal year; Spiriva Respimat® made significant progress and will also be filed this fiscal year, with a potential FY29 launch subject to Paragraph IV outcome. Trelegy® is the next major target applying Breo® learnings, and follow-on Respimat products become easier after the first filing. FDA is looking to expedite approvals for complex generic products with no competition.
• FY27–FY29 launch cadence: FY27 brings Pegfilgrastim (H2), Dalbavancin, Fluticasone nasal spray (Rx), Sugammadex, Epinephrine, Raltegravir (exclusive FTF), and Eribulin. FY28 adds full-year Pegfilgrastim, Diazepam nasal spray, Epinephrine nasal spray, Apixaban, iron sucrose, Saxenda®, Ivacaftor (exclusive FTF), and Midazolam nasal spray. FY29 brings more biosimilars and Dulera®/Spiriva Respimat®.
• India innovation aspiration: A 10-year goal of USD 1 bn or one-third of India revenues from novel proprietary products, built on 60–70 launches. The next three years will contribute a very small fraction, with profitability expected to be similar to or better than the base India business.

Vinita Gupta: "It could potentially get there." (on whether Apixaban 505(b)(2) could reach Mirabegron/Tolvaptan size)

Margins: Up YoY, with Cost Headwinds Ahead

• Gross margin expansion: Improved 330 bps YoY to 74.6%, driven by better product mix, higher India profitability, increased volumes, and cost efficiencies. Q1 was not materially impacted by geopolitical cost increases because of carried-forward inventories; those costs will flow through in coming quarters.
• Staff costs jump: Employee benefit expenses rose 28% YoY to INR 1,383 crores, attributable to annual increments, recruitment for business growth including India field force expansion, and FX impact versus the prior year.
• Adjacencies drag: Diagnostics, Digital, OTC, and CDMO businesses are currently loss-making and weighing on EBITDA margins and EPS. Diagnostics is expected to break even next year, and management expects overall adjacency losses to be a thing of the past in quarters to come.
• Full-year EBITDA guide: Reiterated at ~25%, with quarter-to-quarter volatility expected. Management acknowledged the possibility of dips but declined to quantify the magnitude, and noted that the 24–25% range remains the working assumption.

Ramesh Swaminathan: "I think you would do well to remember that all of these are at this stage loss making and therefore is impacting EBITDA margins and of course, our overall EPS at this stage. But clearly, that would be a thing of the past in quarters to come."

Capital Allocation & Balance Sheet

• Net cash declined: Net cash fell to INR 2,831 crores from INR 4,636 crores, largely due to the VISUfarma acquisition closing during the quarter. VISUfarma began consolidating in Q1 financials.
• ROCE improved: Rose to 29.5% from 28.4% at FY26 end, reflecting the quarter's strong operating performance.
• Strategic capital deployment: Management continues to explore strategic allocation of capital, including on the specialty front, while R&D is guided to ~8% of sales for the full year.
• Regulatory milestones: Received EIRs with VAI status for both Ankleshwar and Somerset from the U.S. FDA during the quarter. Pithampur Unit II remains on track with remediation.

Guidance & Commitments

Key Metrics